• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Request Free Sample

    ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Myasthenia Gravis Market

    ID: MRFR/HC/47606-HCR
    200 Pages
    Garvit Vyas
    September 2025

    US Myasthenia Gravis Market Research Report By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous) and By End User (Hospitals, Specialty Clinics, Homecare Settings)

    Share:

    Download PDF

    ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Myasthenia Gravis Market -Forecast to 2035 Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    US Myasthenia Gravis Market Summary

    The US Myasthenia Gravis market is projected to grow from 500 USD Million in 2024 to 1000 USD Million by 2035.

    Key Market Trends & Highlights

    US Myasthenia Gravis Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate of 6.5 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1000 USD Million, doubling from its 2024 value.
    • In 2024, the market is valued at 500 USD Million, indicating a robust growth trajectory.
    • Growing adoption of innovative therapies due to increasing prevalence of Myasthenia Gravis is a major market driver.

    Market Size & Forecast

    2024 Market Size 500 (USD Million)
    2035 Market Size 1000 (USD Million)
    CAGR (2025-2035) 6.5%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Bristol Myers Squibb, Novartis, Sunovion Pharmaceuticals, Merck and Co., Grifols, Eli Lilly and Company, Horizon Therapeutics, UCB, Pfizer, Alexion Pharmaceuticals, Amgen, Roche, Johnson and Johnson, Mylan, Teva Pharmaceuticals

    US Myasthenia Gravis Market Trends

    The US Myasthenia Gravis market is experiencing several noteworthy trends primarily driven by the increasing prevalence of the condition within the population. The rising awareness surrounding Myasthenia Gravis is catalyzing demand for effective diagnostic and treatment options. The impact of social media and patient advocacy groups has educated both patients and healthcare providers about symptoms, leading to earlier diagnosis and improved patient outcomes.

    Additionally, advancements in treatment, such as the introduction of new drug therapies, are reshaping the treatment landscape. Regulatory approvals for innovative therapies illustrate a growing commitment to addressing unmet needs in the Myasthenia Gravis space. Some of the most recent opportunities in the US market include personalized medicine and targeted therapies.

    The research and clinical study activities directed at the genetic markers related to Myasthenia Gravis might lead toward more individualized treatment strategies. In addition, the development in the delivery of health care services, including telemedicine and mobile health services, is achieving new heights in terms of patient management and monitoring. These technological solutions are crucial due to the intermittent symptoms of Myasthenia Gravis, enabling the required support to be offered whenever needed.

    Moreover, the growing interest in financing biotech companies that focus on disorders of the muscles and the nerves expands business opportunities. Federal and state funding for research on autoimmune diseases underlines the importance placed on discovering better management strategies.

    Overall, the convergence of technological advancement, research initiative growth, and heightened stakeholder engagement reflects an optimistic trajectory for the Myasthenia Gravis market in the US. There is a palpable sense of momentum as the healthcare community rallies around transformative solutions for improving patient care.

    US Myasthenia Gravis Market Drivers

    Market Segment Insights

    Myasthenia Gravis Market Disease Type Insights

    The US Myasthenia Gravis Market is largely segmented by disease type, addressing the distinct variations of this neuromuscular disorder, which impacts patient management and treatment strategies. Among the most prevalent classifications of Myasthenia Gravis, Acetylcholine Receptor Antibody Positive Myasthenia Gravis is often recognized as the dominant form, accounting for a significant share of cases. This type is characterized by the presence of antibodies against the acetylcholine receptor, leading to the hallmark symptoms of muscle weakness and fatigue.

    In contrast, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, while less common, is noteworthy for its distinct pathophysiology and often presents with symptoms that may vary from the acetylcholine receptor form. This means there are important differences in therapeutic needs, requiring specialized treatment approaches such as additional immunosuppressive therapy.

    Seronegative Myasthenia Gravis, which includes cases achieving a diagnosis despite testing negative for the common antibodies, represents an area of ongoing research and clinical interest. This segment is particularly significant because understanding its etiology and the underlying mechanisms continues to evolve, creating both challenges and opportunities in terms of effective management and treatment.

    The prevalence and clinical implications associated with these disease types underline the need for precise diagnostic tools and therapies, as each one requires tailored management strategies that reflect their distinct pathophysiological features. Moreover, the presence of these different disease types emphasizes the diversification currently seen within the US Myasthenia Gravis Market, driving innovation in treatment options and reflecting the growing awareness of the need for personalized medicine. The intricate interplay among these disease types fosters opportunities for novel therapeutic developments, empowering healthcare providers to improve patient outcomes through targeted approaches.

    Myasthenia Gravis Market Treatment Type Insights

    The US Myasthenia Gravis Market is categorized into various treatment types that cater to the diverse needs of patients. Anticholinesterase Agents play a crucial role in symptomatic management, enhancing neuromuscular transmission and providing immediate relief to patients. Immunosuppressants are significant due to their ability to modify the disease course, reducing the immune response that contributes to muscle weakness.

    Intravenous Immunoglobulin offers a rapid treatment option for severe exacerbations, making it a vital component in urgent care scenarios. Plasmapheresis serves as an important approach for providing short-term improvement, especially before surgical interventions or during acute phases. Thymectomy, often indicated for patients with thymoma or generalized myasthenia gravis, significantly alleviates symptoms by targeting thymic factors contributing to autoimmunity. This diverse segmentation addresses the clinical heterogeneity of Myasthenia Gravis, with each treatment type offering distinct advantages depending on patient-specific conditions.

    The focus on innovation in these treatment modalities is expected to support market growth, driven by advancements in medical technology and increasing awareness of the disease among healthcare providers in the US.

    Myasthenia Gravis Market Route of Administration Insights

    The Route of Administration is a critical segment within the US Myasthenia Gravis Market, influencing treatment efficacy and patient compliance. As the market evolves, various methods such as Oral, Intravenous, and Subcutaneous administration are making an impact on healthcare delivery. Oral administration, due to its user-friendly nature, often sees significant adoption, enhancing adherence among patients.

    Intravenous routes, while less convenient, can deliver medications more rapidly into the systemic circulation, which is essential for acute management cases. Subcutaneous administration also holds importance, providing a balance between convenience and efficacy and facilitating self-administration options for patients. These administration methods play vital roles in achieving optimal therapeutic outcomes, as they align with varying patient needs and treatment protocols. The ongoing advancements in formulation technology and delivery systems contribute to enhanced drug absorption and improved patient experiences, marking a transformative shift in the US Myasthenia Gravis Market landscape.

    With the rise in patient-centric approaches, these routes are expected to change the dynamics of treatment delivery significantly while addressing the diverse needs of the growing patient population in the United States.

    Myasthenia Gravis Market End User Insights

    The US Myasthenia Gravis Market, particularly within the End User segment, demonstrates a dynamic landscape characterized by various healthcare settings such as Hospitals, Specialty Clinics, and Homecare Settings. Hospitals play a pivotal role in the management of Myasthenia Gravis, typically serving as the primary institution for diagnosis and intensive treatment options, thereby establishing their significance in the overall market.

    Specialty Clinics, on the other hand, offer targeted therapies and specialized care tailored specifically for Myasthenia Gravis patients, often providing innovative treatment methods and dedicated neurologists who maintain a close relationship with patients to optimize care and outcomes. Homecare Settings are increasingly important, especially considering the growing trend towards personalized healthcare and patient convenience, allowing individuals to receive necessary care in the comfort of their own homes, which enhances their quality of life and adherence to treatment protocols.

    As the population ages and awareness of Myasthenia Gravis grows, the demand across these End User settings is expected to rise, influencing the overall US Myasthenia Gravis Market revenue. The integration of advanced technologies, comprehensive care plans, and an emphasis on patient-centered approaches will further support market growth and enhance the treatment experience.

    Get more detailed insights about US Myasthenia Gravis Market -Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The US Myasthenia Gravis Market is characterized by a dynamic and rapidly evolving competitive landscape, driven largely by advancements in treatment options and an increasing understanding of the disease's pathophysiology. Myasthenia Gravis, an autoimmune neuromuscular disorder, presents unique challenges that have spurred pharmaceutical companies to invest heavily in research and development to create innovative therapies targeting this condition. With a rising patient population and a growing focus on personalized medicine, companies in the US market are exploring novel biologics, small molecules, and immunotherapies, leading to intense competition.

    The collaborations between biotech firms and larger pharmaceutical companies also play a crucial role in enhancing product portfolios and improving market accessibility. Regulatory approvals from agencies such as the FDA lend significant credibility to those companies successfully bringing effective treatments to market, further intensifying competition.

    Bristol Myers Squibb

    Bristol Myers Squibb has established itself as a leader in the US Myasthenia Gravis Market, primarily through its commitment to research and the development of effective therapeutic options. The company has made significant contributions to the understanding and treatment of this debilitating disease, with a strong focus on delivering innovative therapies aimed at enhancing patients' quality of life. Bristol Myers Squibb's presence in the market is reinforced by its robust pipeline and strategic partnerships that allow for the continuous evolution of its product offerings.

    The company's strengths lie in its extensive experience in hematology and oncology, which are closely aligned with autoimmunity therapies. Their robust clinical trials and a positive reputation among healthcare professionals further bolster their competitive position in the Myasthenia Gravis Market within the United States.

    Novartis

    Novartis is another prominent player in the US Myasthenia Gravis Market, known for its comprehensive approach to addressing the complexities surrounding this condition. The company offers key products and services specifically tailored to Myasthenia Gravis management, focusing on both acute and chronic treatment regimens. Novartis has built a strong market presence due to its innovative drug development strategies and an emphasis on patient-centered care, supporting healthcare providers with educational resources and tools.

    The company's strengths lie not only in its established portfolio but also in its strategic mergers and acquisitions, which have expanded its capabilities and enhanced its research initiatives in neurology. Such strategic moves enable Novartis to maintain competitiveness and drive advancements in treating Myasthenia Gravis, positioning them favorably within the US market landscape.

    Key Companies in the US Myasthenia Gravis Market market include

    Industry Developments

    Market Segmentation

    Myasthenia Gravis Market End User Outlook

    • Hospitals
    • Specialty Clinics
    • Homecare Settings

    Myasthenia Gravis Market Disease Type Outlook

    • Acetylcholine Receptor Antibody Positive Myasthenia Gravis
    • Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
    • Seronegative Myasthenia Gravis

    Myasthenia Gravis Market Treatment Type Outlook

    • Anticholinesterase Agents
    • Immunosuppressants
    • Intravenous Immunoglobulin
    • Plasmapheresis
    • Thymectomy

    Myasthenia Gravis Market Route of Administration Outlook

    • Oral
    • Intravenous
    • Subcutaneous

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 413.7(USD Million)
    MARKET SIZE 2024 500.0(USD Million)
    MARKET SIZE 2035 1000.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.504% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Bristol Myers Squibb, Novartis, Sunovion Pharmaceuticals, Merck and Co., Grifols, Eli Lilly and Company, Horizon Therapeutics, UCB, Pfizer, Alexion Pharmaceuticals, Amgen, Roche, Johnson and Johnson, Mylan, Teva Pharmaceuticals
    SEGMENTS COVERED Disease Type, Treatment Type, Route of Administration, End User
    KEY MARKET OPPORTUNITIES Novel therapies development, Improved diagnostic tools, Increased awareness campaigns, Enhanced patient support services, Expanding telehealth solutions
    KEY MARKET DYNAMICS increasing patient population, rising healthcare expenditure, advancements in treatment options, growing awareness and diagnosis, strong research and development efforts
    COUNTRIES COVERED US

    Market Highlights

    Author

    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch

    Leave a Comment

    FAQs

    What is the expected market size of the US Myasthenia Gravis Market in 2024?

    The US Myasthenia Gravis Market is expected to be valued at 500.0 USD Million in 2024.

    What market size is projected for the US Myasthenia Gravis Market by 2035?

    By 2035, the US Myasthenia Gravis Market is projected to reach a value of 1000.0 USD Million.

    What is the expected CAGR for the US Myasthenia Gravis Market from 2025 to 2035?

    The US Myasthenia Gravis Market is expected to grow at a CAGR of 6.504% from 2025 to 2035.

    What are the key disease type segments in the US Myasthenia Gravis Market?

    The key disease type segments include Acetylcholine Receptor Antibody Positive, Muscle-Specific Kinase Antibody Positive, and Seronegative Myasthenia Gravis.

    Which segment holds the largest market share in the US Myasthenia Gravis Market in 2024?

    In 2024, the Acetylcholine Receptor Antibody Positive segment is expected to dominate with a market value of 210.0 USD Million.

    What market value is anticipated for the Muscle-Specific Kinase Antibody Positive Myasthenia Gravis segment by 2035?

    The Muscle-Specific Kinase Antibody Positive segment is expected to reach a market value of 300.0 USD Million by 2035.

    What is the projected market size for the Seronegative Myasthenia Gravis segment in 2024?

    The Seronegative Myasthenia Gravis segment is projected to have a market size of 140.0 USD Million in 2024.

    Who are the major players in the US Myasthenia Gravis Market?

    Major players include Bristol Myers Squibb, Novartis, Sunovion Pharmaceuticals, and Merck and Co., among others.

    What growth opportunities exist in the US Myasthenia Gravis Market?

    Emerging trends and advancements in treatment options present significant growth opportunities in the market.

    How do market trends affect the growth of the US Myasthenia Gravis Market?

    Current trends and innovations in drug development positively influence the growth of the US Myasthenia Gravis Market.

    1. |- Table of Contents   EXECUTIVE SUMMARY Market Overview Key Findings Market Segmentation Competitive Landscape Challenges and Opportunities Future Outlook     MARKET INTRODUCTION Definition Scope of the study Research Objective Assumption Limitations RESEARCH METHODOLOGY Overview Data Mining Secondary Research Primary Research Primary Interviews and Information Gathering Process Breakdown of Primary Respondents Forecasting Model Market Size Estimation Bottom-Up Approach Top-Down Approach Data Triangulation Validation     MARKET DYNAMICS Overview Drivers Restraints Opportunities MARKET FACTOR ANALYSIS Value chain Analysis Porter's Five Forces Analysis Bargaining Power of Suppliers Bargaining Power of Buyers Threat of New Entrants Threat of Substitutes Intensity of Rivalry COVID-19 Impact Analysis Market Impact Analysis Regional Impact Opportunity and Threat Analysis     US Myasthenia Gravis Market, BY Disease Type (USD Million) Acetylcholine Receptor Antibody Positive Myasthenia Gravis Muscle-Specific Kinase Antibody Positive Myasthenia Gravis Seronegative Myasthenia Gravis US Myasthenia Gravis Market, BY Treatment Type (USD Million) Anticholinesterase Agents Immunosuppressants Intravenous Immunoglobulin Plasmapheresis Thymectomy US Myasthenia Gravis Market, BY Route of Administration (USD Million) Oral Intravenous Subcutaneous US Myasthenia Gravis Market, BY End User (USD Million) Hospitals Specialty Clinics Homecare Settings     Competitive Landscape Overview Competitive Analysis Market share Analysis Major Growth Strategy in the Myasthenia Gravis Market Competitive Benchmarking Leading Players in Terms of Number of Developments in the Myasthenia Gravis Market Key developments and growth strategies New Product Launch/Service Deployment Merger & Acquisitions Joint Ventures Major Players Financial Matrix Sales and Operating Income Major Players R&D Expenditure. 2023 Company Profiles Bristol Myers Squibb Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Novartis Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Sunovion Pharmaceuticals Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Merck and Co. Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Grifols Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Eli Lilly and Company Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Horizon Therapeutics Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies UCB Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Pfizer Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Alexion Pharmaceuticals Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Amgen Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Roche Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Johnson and Johnson Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Mylan Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Teva Pharmaceuticals Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Appendix References Related Reports LIST Of tables   LIST OF ASSUMPTIONS US Myasthenia Gravis Market SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2035 (USD Billions) US Myasthenia Gravis Market SIZE ESTIMATES & FORECAST, BY TREATMENT TYPE, 2019-2035 (USD Billions) US Myasthenia Gravis Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD Billions) US Myasthenia Gravis Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions) PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL ACQUISITION/PARTNERSHIP                                                           LIST Of figures   MARKET SYNOPSIS US MYASTHENIA GRAVIS MARKET ANALYSIS BY DISEASE TYPE US MYASTHENIA GRAVIS MARKET ANALYSIS BY TREATMENT TYPE US MYASTHENIA GRAVIS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION US MYASTHENIA GRAVIS MARKET ANALYSIS BY END USER KEY BUYING CRITERIA OF MYASTHENIA GRAVIS MARKET RESEARCH PROCESS OF MRFR DRO ANALYSIS OF MYASTHENIA GRAVIS MARKET DRIVERS IMPACT ANALYSIS: MYASTHENIA GRAVIS MARKET RESTRAINTS IMPACT ANALYSIS: MYASTHENIA GRAVIS MARKET SUPPLY / VALUE CHAIN: MYASTHENIA GRAVIS MARKET MYASTHENIA GRAVIS MARKET, BY DISEASE TYPE, 2025 (% SHARE) MYASTHENIA GRAVIS MARKET, BY DISEASE TYPE, 2019 TO 2035 (USD Billions) MYASTHENIA GRAVIS MARKET, BY TREATMENT TYPE, 2025 (% SHARE) MYASTHENIA GRAVIS MARKET, BY TREATMENT TYPE, 2019 TO 2035 (USD Billions) MYASTHENIA GRAVIS MARKET, BY ROUTE OF ADMINISTRATION, 2025 (% SHARE) MYASTHENIA GRAVIS MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2035 (USD Billions) MYASTHENIA GRAVIS MARKET, BY END USER, 2025 (% SHARE) MYASTHENIA GRAVIS MARKET, BY END USER, 2019 TO 2035 (USD Billions) BENCHMARKING OF MAJOR COMPETITORS  

    US Myasthenia Gravis Market Segmentation

    • Myasthenia Gravis Market By Disease Type (USD Million, 2019-2035)

      • Acetylcholine Receptor Antibody Positive Myasthenia Gravis
      • Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
      • Seronegative Myasthenia Gravis

    • Myasthenia Gravis Market By Treatment Type (USD Million, 2019-2035)

      • Anticholinesterase Agents
      • Immunosuppressants
      • Intravenous Immunoglobulin
      • Plasmapheresis
      • Thymectomy

    • Myasthenia Gravis Market By Route of Administration (USD Million, 2019-2035)

      • Oral
      • Intravenous
      • Subcutaneous

    • Myasthenia Gravis Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Specialty Clinics
      • Homecare Settings
    Report Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027